Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma

NCT03056001 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Soft Tissue Sarcoma, Adult
Soft Tissue Sarcoma, Child

Interventions

DRUG: Pembrolizumab
DRUG: Doxorubicin

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]